Progressive Multiple Sclerosis (PMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Progressive multiple sclerosis (PMS) represents a clinical variant of MS characterized by a gradual accumulation of disability, independent of relapses, over time. Secondary progressive MS (SPMS) emerges after an initial relapsing phase of the disease, while primary progressive MS (PPMS) manifests with a gradual disability accrual from disease onset. PPMS constitutes the initial disease presentation in approximately 10% of patients, and a substantial proportion of individuals with relapsing-remitting MS (RRMS) eventually transition to SPMS. Unlike the significant progress in managing RRMS, where inflammation can be targeted to modify the disease course, no specific treatment has been identified for purely progressive forms of MS. This therapeutic gap highlights an incomplete understanding of PMS pathogenesis, a lack of validated outcome measures, and predominantly adverse clinical trial outcomes.

Thelansis’s “Progressive Multiple Sclerosis (PMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Multiple Sclerosis (PMS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Progressive Multiple Sclerosis (PMS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Progressive Multiple Sclerosis (PMS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Progressive Multiple Sclerosis (PMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033